JP2023544853A - 局所眼科用組成物 - Google Patents

局所眼科用組成物 Download PDF

Info

Publication number
JP2023544853A
JP2023544853A JP2023521587A JP2023521587A JP2023544853A JP 2023544853 A JP2023544853 A JP 2023544853A JP 2023521587 A JP2023521587 A JP 2023521587A JP 2023521587 A JP2023521587 A JP 2023521587A JP 2023544853 A JP2023544853 A JP 2023544853A
Authority
JP
Japan
Prior art keywords
atropine
topical ophthalmic
ophthalmic composition
eye
myopia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544853A5 (https=
Inventor
ニ，ジンソン
ヤン，ロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADS Therapeutics LLC
Original Assignee
ADS Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADS Therapeutics LLC filed Critical ADS Therapeutics LLC
Publication of JP2023544853A publication Critical patent/JP2023544853A/ja
Publication of JP2023544853A5 publication Critical patent/JP2023544853A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023521587A 2020-10-08 2021-10-08 局所眼科用組成物 Pending JP2023544853A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089263P 2020-10-08 2020-10-08
US63/089,263 2020-10-08
US17/317,551 2021-05-11
US17/317,551 US11191751B1 (en) 2020-10-08 2021-05-11 Topical ophthalmological atropine free base compositions
PCT/US2021/054221 WO2022076852A1 (en) 2020-10-08 2021-10-08 Topical ophthalmological compositions

Publications (2)

Publication Number Publication Date
JP2023544853A true JP2023544853A (ja) 2023-10-25
JP2023544853A5 JP2023544853A5 (https=) 2024-10-10

Family

ID=78818588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521587A Pending JP2023544853A (ja) 2020-10-08 2021-10-08 局所眼科用組成物

Country Status (11)

Country Link
US (2) US11191751B1 (https=)
EP (2) EP4225284B1 (https=)
JP (1) JP2023544853A (https=)
KR (1) KR20230084190A (https=)
CN (1) CN116390714A (https=)
AU (1) AU2021359003A1 (https=)
BR (1) BR112023006371A2 (https=)
CA (1) CA3193940A1 (https=)
ES (1) ES3063371T3 (https=)
MX (1) MX2023004065A (https=)
WO (1) WO2022076852A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511695A (ja) * 2021-02-03 2024-03-15 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
KR20240136369A (ko) * 2022-01-21 2024-09-13 에이디에스 테라퓨틱스 엘엘씨 8-메틸-8-아자비사이클로[3.2.1] 옥탄-3-일의 에스테르 3-하이드록시-2-페닐프로파노에이트
JP2025541009A (ja) 2022-12-23 2025-12-17 ノバリック ゲーエムベーハー ヒヨスチアミンを含む半フッ化アルカン組成物
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025264886A1 (en) * 2024-06-19 2025-12-26 Btv Holding, Llc Ophthalmic preparations and methods of use
WO2026011139A1 (en) * 2024-07-05 2026-01-08 Ads Therapeutics Llc Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
JP2015531344A (ja) * 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物
JP2017522292A (ja) * 2014-06-24 2017-08-10 シドネキシス，インク． 眼科用組成物
WO2020074697A1 (en) * 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020160493A2 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) * 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
WO2019068763A1 (en) * 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
TW201932104A (zh) * 2017-11-03 2019-08-16 澳大利亞商布萊恩荷登視覺協會 用於控制及/或降低近視進展之醫藥組合物
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) * 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
JP2015531344A (ja) * 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物
JP2017522292A (ja) * 2014-06-24 2017-08-10 シドネキシス，インク． 眼科用組成物
WO2020074697A1 (en) * 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020160493A2 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRITTANY J CARR; ET AL: "MYOPIA-INHIBITING CONCENTRATIONS OF MUSCARINIC RECEPTOR ANTAGONISTS BLOCK ACTIVATION OF 以下備考", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. VOL.59, NR.7, JPN5024009446, June 2018 (2018-06-01), pages 2778 - 2791, ISSN: 0005726649 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511695A (ja) * 2021-02-03 2024-03-15 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物
JP7749020B2 (ja) 2021-02-03 2025-10-03 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物
US12485177B2 (en) 2021-02-03 2025-12-02 Ads Therapeutics Llc Topical ophthalmological compositions

Also Published As

Publication number Publication date
CN116390714A (zh) 2023-07-04
US20230355594A1 (en) 2023-11-09
EP4706766A2 (en) 2026-03-11
CA3193940A1 (en) 2022-04-14
EP4225284B1 (en) 2025-11-26
WO2022076852A1 (en) 2022-04-14
AU2021359003A1 (en) 2023-05-04
ES3063371T3 (en) 2026-04-16
US11191751B1 (en) 2021-12-07
EP4225284C0 (en) 2025-11-26
KR20230084190A (ko) 2023-06-12
BR112023006371A2 (pt) 2023-05-09
EP4225284A1 (en) 2023-08-16
MX2023004065A (es) 2023-05-03
AU2021359003A9 (en) 2024-06-13
EP4225284A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
JP2023544853A (ja) 局所眼科用組成物
US12485177B2 (en) Topical ophthalmological compositions
JP7353292B2 (ja) ネビボロールを含む医薬組成物
AU2023203933B2 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
TW202412797A (zh) 眼用組合物
JP7801201B2 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
US20250134881A1 (en) Treatment of ocular inflammatory diseases using laquinimod
Okka et al. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
Vale et al. Drugs and the Eye: Sponsored by the British Optical Association
US20260124305A1 (en) Topical ophthalmological compositions
HK40086649A (zh) 局部眼科组合物
CN120093684A (zh) 局部眼科组合物
Zhang et al. Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression
WO2026018131A1 (en) Ocular compositions
HK40126394A (zh) 一种α-肾上腺素受体激动剂眼用组合物及其用途
WO2025163485A1 (en) Ophthalmic pharmaceutical composition
CN115702879A (zh) 一种硫酸阿托品的滴眼液
CN114028421A (zh) 一种使用泊洛沙姆用于治疗眼部疾病的方法
TR201612233A1 (tr) Oftalmi̇k farmasöti̇k bi̇leşi̇mler

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260205